In this webinar, Dr. Eliaz presents groundbreaking research findings and practice-tested protocols to effectively manage Galectin-3, including the use of selective apheresis showing breakthrough results against life-threatening sepsis and other pro-inflammatory conditions. He will also discuss benefits, risks, and common misconceptions related to apheresis.
Why do two patients with similar metabolic profiles sometimes respond so differently to the same GLP-1 medication? Galectin-3 may offer an important clue. This emerging biomarker provides insight into the inflammatory and fibrotic “metabolic terrain” that may influence GLP-1 treatment response.
Modified Citrus Pectin Blocks Gal-3 to Protect Against Post-Stroke Brain Injury A growing body of data points to microglial neuroinflammation as a contributing factor in ischemic stroke injury — driven by high levels of galectin-3 (Gal-3), a master proinflammatory alarmin protein. Research shows that Gal-3 promotes unregulated microglial activation andRead
